Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Palantir Shares Face Steep Decline Amid Valuation Concerns

Robert Sasse by Robert Sasse
November 29, 2025
in AI & Quantum Computing, Analysis, Nasdaq, Tech & Software
0
Palantir Stock
0
SHARES
26
VIEWS
Share on FacebookShare on Twitter

The investment landscape for Palantir Technologies Inc. shifted dramatically in November, as the data analytics firm experienced its most severe monthly decline in over two years. Previously regarded as an unstoppable force in the artificial intelligence sector, the company now finds itself at the center of a heated debate between its chief executive and a prominent hedge fund manager, leaving investors to question whether this represents a buying opportunity or the end of an era.

Strong Fundamentals Clash With Market Sentiment

Paradoxically, Palantir’s operational performance remains robust. The company’s latest quarterly report significantly exceeded Wall Street’s expectations across multiple metrics:
* Revenue surged by 63 percent year-over-year
* Commercial revenue in the United States exploded by 121 percent
* Adjusted earnings per share doubled compared to previous periods

Despite these strong results and an upward revision to annual forecasts, including major contract wins with organizations like PwC UK, investor confidence has been undermined by concerns over the company’s valuation. The situation was further complicated by insider selling activity, with CEO Alex Karp and other executives divesting portions of their holdings during November.

Sector-Wide Rotation Hits AI Stocks

The downturn reflects broader market dynamics rather than company-specific issues alone. November witnessed a significant sector rotation as investors retreated from highly-valued AI securities. Even industry heavyweights including Nvidia and Microsoft saw their share prices retreat during this period.

Market analysts have expressed growing apprehension about valuation levels. Researchers at Jefferies have characterized current pricing as “extreme,” while Deutsche Bank has voiced skepticism about how such astronomical metrics can be justified. With a price-to-earnings ratio that exceeds conventional investment parameters and a Relative Strength Index approaching 79—indicating severely overbought conditions—the risk profile has increased substantially.

Should investors sell immediately? Or is it worth buying Palantir?

High-Profile Clash Highlights Diverging Views

Amid this turbulent backdrop, a public dispute has emerged between Palantir’s leadership and notable investor Michael Burry. The fund manager, who gained fame for his successful bet against the housing market in 2008, has established substantial put options against Palantir with a notional value approaching $1 billion as disclosed in late September.

The response from Palantir’s executive suite was immediate and forceful. Chief Executive Officer Alex Karp used two separate television appearances within a single week to denounce Burry’s position as “completely insane” and implicitly accused him of market manipulation. Burry countered in his latest investment newsletter, arguing that markets have fundamentally misjudged both the lifespan of AI chips and the depreciation cycles affecting major technology firms—a direct challenge to the foundation of the current AI investment boom.

Market Performance and Outlook

Palantir shares concluded recent trading at 145.54 euros, reflecting a decline exceeding 15 percent over a 30-day window. Despite this pullback, the equity maintains a substantial gain of nearly 99 percent since the beginning of the year.

The investment community remains deeply divided. On one side stand impressive operational growth figures and expanding business opportunities. On the other, stretched valuations that permit no margin for error and influential short sellers betting on a substantial correction. Market participants should prepare for continued volatility until the tension between fundamental valuation concerns and AI-driven optimism reaches resolution.

Ad

Palantir Stock: Buy or Sell?! New Palantir Analysis from February 8 delivers the answer:

The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Palantir: Buy or sell? Read more here...

Tags: Palantir
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
Redcare Pharmacy Stock

Redcare Pharmacy Shares Show Signs of Recovery After Steep Decline

Silber Preis Stock

Silver Soars to Unprecedented Heights as Supply Squeeze Intensifies

Figma Stock

Figma Shares Navigate Critical Juncture After Steep Decline

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com